Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

QUARTZ: Comparative Effectiveness of Switching From Albuterol to Albuterol/Budesonide Versus Adding Low-Dose Inhaled Corticosteroids or Leukotriene Receptor Antagonists to Albuterol Among Adults With Asthma in the United States

NCT07787117 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT07787117
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07787117 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
QUARTZ: Comparative Effectiveness of Switching From Albuterol to Albuterol/Budesonide Versus Adding Low-Dose Inhaled Corticosteroids or Leukotriene Receptor Antagonists to Albuterol Among Adults With Asthma in the United States
Lead sponsor
AstraZeneca
Phase
Observational
Overall status
Recruiting
Start date
August 3, 2026
Completion date
September 30, 2026
Enrollment
8,000 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

asthma